长春高新收到Yarrow7000万美元首笔付款

Core Viewpoint - Changchun Gaoxin has received a $70 million upfront payment from Yarrow Bioscience for the exclusive licensing agreement related to the GenSci098 injection project, enhancing the company's cash reserves and supporting its future R&D and international strategy [1] Group 1 - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has a wholly-owned subsidiary, Shanghai Saizeng Medical Technology, which entered into an exclusive licensing agreement with Yarrow Bioscience for the GenSci098 injection project [1] - The agreement grants Yarrow exclusive rights to develop, produce, and commercialize GenSci098 injection globally, excluding Greater China [1] - The payment received will further strengthen the company's cash reserves and assist in advancing its pipeline development and international strategy [1]